Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Rectal Cancer
•
Medical Oncology
•
Colorectal Cancer
Are there any data (retrospective or otherwise) on the watch and wait approach in patients who achieve cCR after CRT without consolidation chemotherapy?
What is the risk of distant relapse?
Related Questions
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Is there any circumstance where you would consider bevacizumab in patients with locally advanced colorectal cancer with rectouterine fistula?
For a patient with metastatic colon cancer which is MSI-H/dMMR and BRAF V600E+, what would be your preferred first line treatment?
What systemic therapy would you use in T3N1M1 MMR proficient rectal cancer with solitary liver lesion when going for curative intent (chemo>short course RT> resection of primary and liver met)?
In a patient with metastatic colorectal cancer to the lung and liver, is there a role for liver directed therapy if the lung is not amenable to local therapy?
What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?
Would you consider circulating DNA assay in resected node-negative deficient MMR colon cancer off-trial to guide your treatment?
Is there a role of adjuvant or systemic therapy for patients with resected stage I colon cancer with subsequent local recurrence S/P a second resection and now has NED?
Are there any adverse risk factors in stage I colon cancer that would warrant ctDNA testing?
Would you change treatment approach for rectal cancer with an associated intussusception?